CABERGOLINE for endometriosis

Hypothesized mechanism

Cabergoline acts as a dopamine D2 receptor agonist, a pathway that may be relevant to endometriosis (potentially via antiangiogenic effects), though the mechanistic link to the phenotype is not detailed in the claims.

This is the model’s proposed mechanism from the sources on file, not a demonstrated causal pathway. How well the published record supports it is reflected in the rigor and plausibility dimensions of the score, and traced to the verbatim sources at the foot of the page.

Independent reading, reported beside the score

One outside model cross-reference is reported alongside the composite score. It is recorded separately and is not combined into the score.

Source evidence · what the pipeline ingested

These are the sources the pipeline ingested to detect and score this signal, the published literature the model actually read, each tagged by study type. Where the model combined findings the claim is marked as a synthesis (S), and where the literature disagrees the contradiction is shown (!).

Every source below belongs to this signal’s evidence arm, Pathway insights. Whel reads each drug-condition pair through four such arms, each held to its own inclusion bar; a signal is surfaced through one of them.

• 1Per Open Targets (retrieved 2026-06-16), CABERGOLINE (a Small molecule) is a clinical candidate for endometriosis (maximum clinical stage PHASE_2); its mechanism of action is Dopamine D2 receptor agonist on target dopamine receptor D2. Open Targets · mechanistic ↗
• 2In FDA AEMS (the FDA Adverse Event Reporting System, formerly FAERS; retrieved 2026-06-16), 59 report(s) of ABDOMINAL PAIN were recorded for CABERGOLINE among female patients (of 2498 female reports for CABERGOLINE in the analysed sample). This is a raw adverse-event report count, not a disproportionality statistic or evidence of causation, and is subject to reporting bias and confounding. Read two ways: as a safety consideration, and — because it suggests CABERGOLINE acts on a system relevant to endometriosis — as a mechanistic lead for further investigation, not evidence of benefit. AEMS · adverse-event report ↗
• 3In FDA AEMS (the FDA Adverse Event Reporting System, formerly FAERS; retrieved 2026-06-16), 38 report(s) of ABDOMINAL DISTENSION were recorded for CABERGOLINE among female patients (of 2498 female reports for CABERGOLINE in the analysed sample). This is a raw adverse-event report count, not a disproportionality statistic or evidence of causation, and is subject to reporting bias and confounding. Read two ways: as a safety consideration, and — because it suggests CABERGOLINE acts on a system relevant to endometriosis — as a mechanistic lead for further investigation, not evidence of benefit. AEMS · adverse-event report ↗
• 4Per SIDER (the Side Effect Resource, from pre-2015 drug labels), CABERGOLINE lists Abdominal pain as a labeled side effect, reported in 5.0% of participants. SIDER 4.1 is a 2015 snapshot, so newer drugs may be unrepresented; this is a label-derived association, not causation in any individual. Read two ways: as a safety consideration, and — because it suggests CABERGOLINE acts on a system relevant to endometriosis — as a mechanistic lead for further investigation, not evidence of benefit. SIDER · label side-effect ↗

These are the verbatim sources the pipeline surfaced and read; they may not be the full published record for a pair, and the score reflects the strength and agreement of the evidence rather than its volume. The strength of these source types is what the rigor dimension of the score reads off. MATRIX, sex-specific pharmacokinetics, and cycle phase are separate layers the pipeline does not ingest, external cross-references reported beside the score, and they link to their own sources in their sections above.